Bullish initiation from a below-average accuracy firm into an already crowded consensus and weakening EPS trends offers limited incremental conviction. With earnings in 3 days and negative institutional flows, the upgrade lacks strong corroboration — treat as noise.
Price Chart
Executive Summary
Canaccord Genuity initiates coverage on AbbVie (ABBV) with a Buy rating and $262 price target, implying 28.6% upside from the current $203.71. The firm’s accuracy is 47% (722/1538), below the 57% average among 15 tracked firms. Consensus is overwhelmingly bullish: 28 of 29 analysts rate ABBV Buy or equivalent (97% Buy-rated), with a mean PT of $249. EPS estimates are declining: 30-day revisions show 7 down, 0 up for current year. Earnings due in 3 days. Insider selling totaled $2.57M in March. Institutional activity mixed: Norges Bank exited, Renaissance Technologies trimmed. Short ratio at 57.1%. Contrarian call from a below-average accuracy firm into weakening EPS trends and negative institutional flows limits signal strength.
Impact Score
Consensus & Targets
Of 29 analysts, 28 rate ABBV as Buy or Strong Buy (97%), and 1 as Hold. No Sell ratings. The consensus is strongly aligned and heavily skewed toward positive sentiment, with 7 Strong Buys and 21 Buys.
The consensus price target mean and median are both $249, with a high of $299 and low of $184. At $203.71, the stock has 22.4% implied upside to the mean. Canaccord’s $262 PT is 5.2% above the mean and 53.9% above the low, placing it in the top quartile of targets.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-21 | Canaccord Genuity | initiate | Buy | $262.00 |
| 2026-04-10 | Guggenheim | maintain | Buy | $249.00 |
| 2026-04-08 | Cantor Fitzgerald | maintain | Overweight | $240.00 |
| 2026-02-25 | RBC Capital | initiate | Outperform | $260.00 |
| 2026-02-20 | Barclays | initiate | Overweight | $275.00 |
| 2026-02-18 | Piper Sandler | maintain | Overweight | $299.00 |
| 2026-02-17 | Freedom Broker | maintain | Buy | $260.00 |
| 2026-02-05 | UBS | maintain | Neutral | $230.00 |
| 2026-02-05 | Evercore ISI Group | maintain | Outperform | $228.00 |
| 2026-02-05 | Morgan Stanley | maintain | Overweight | $270.00 |
Over the past 30 days, there has been 1 upgrade and 0 downgrades. EPS revisions are negative: 7 down, 0 up over the past 30 days for current-year estimates. Forward EPS estimates have declined from $14.54 to $14.33 (0y) and $16.12 to $16.09 (+1y), signaling weakening sentiment despite high ratings.
Firm Track Record — Canaccord Genuity
Canaccord Genuity accuracy: 47% on 1538 calls | avg return: 3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| JP Morgan | 100% | 4/4 | 7.5% | top tier |
| HSBC | 100% | 3/3 | 4.5% | top tier |
| Cantor Fitzgerald | 89% | 8/9 | 9.6% | top tier |
| Wells Fargo | 75% | 3/4 | 0% | top tier |
| BMO Capital | 71% | 5/7 | 4.2% | top tier |
| Evercore ISI Group | 67% | 2/3 | 4.8% | top tier |
| Piper Sandler | 67% | 4/6 | 7.5% | top tier |
| Morgan Stanley | 67% | 6/9 | 4% | top tier |
| Citigroup | 63% | 5/8 | 5.9% | top tier |
| UBS | 60% | 3/5 | -1.2% | above average |
Canaccord Genuity has a 47% accuracy rate (722 correct out of 1538 rated calls), below the average of the 15 tracked firms (57%). Their average return on rated stocks is 3%, below top-tier firms like Cantor Fitzgerald (9.6%) and JP Morgan (7.5%). Among peers, only B of A Securities (20%) has a lower accuracy.
Earnings Estimates
Next earnings: Apr 24, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $2.76 | $2.57 — $3.08 | $14.7B | ↑0 ↓0 |
| +1q | $3.76 | $3.59 — $4.02 | $16.8B | ↑2 ↓0 |
| 0y | $14.33 | $13.97 — $15.00 | $67.1B | ↑0 ↓0 |
| +1y | $16.09 | $14.95 — $17.42 | $72.5B | ↑1 ↓0 |
Cross-Platform Signals
Insiders sold $2.57M in March (Purdue David Ryan: $1.22M; Siatis Perry C: $1.35M). Institutions show divergence: Norges Bank fully exited a $5.87B position, and Renaissance Technologies trimmed by 52.7%, while Cullen Capital added 60.1%. Short interest is high at 57.1% short ratio, suggesting elevated bearish positioning despite analyst optimism.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $260.37 (−0.53%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $260.37 (+0.06%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $260.37 (+6.77%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $260.37 (+6.23%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $260.37 (+6.23%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $260.37 (+3.76%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $260.37 (+1.35%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $260.37 (+13.20%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $260.37 (+24.34%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $260.37 (+27.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access